Related Experiment Video

Updated: Apr 18, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1

Yamei Hu1, Lingxian Wang1, Lu Wang1

  • 1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, China.

Toxicology and Applied Pharmacology
|January 11, 2015
PubMed

Insights

The proteasome inhibitor bortezomib shows greater effectiveness against aggressive liposarcoma cells by enhancing apoptosis. This suggests bortezomib could be a promising treatment for advanced liposarcoma, potentially by targeting SERCA2 and MDR1 pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Liposarcoma is a prevalent soft tissue sarcoma with a high recurrence rate.
  • Limited therapeutic strategies exist for advanced or metastatic liposarcoma.
  • Understanding mechanisms of drug resistance and sensitivity is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the differential cytotoxicity of bortezomib in highly malignant liposarcoma cells.
  • To elucidate the underlying molecular mechanisms of bortezomib's enhanced efficacy.
  • To explore the potential of bortezomib as a therapeutic agent for advanced liposarcoma.

Main Methods:

  • Comparative analysis of bortezomib cytotoxicity in SW872 and SW872-S liposarcoma cell lines.
  • Assessment of apoptotic signaling pathways activation in vitro and in vivo.
  • Evaluation of the role of Jun-N-terminal kinase (JNK) and translation inhibition.
  • Investigation of bortezomib's effect on Multidrug Resistance 1 (MDR1) expression and function.
  • Pharmacological and genetic inhibition of sarco/endoplasmic reticulum calcium-ATPase (SERCA) 2.

Main Results:

  • Bortezomib demonstrated significantly stronger cytotoxicity against highly malignant SW872-S liposarcoma cells compared to parental SW872 cells.
  • Enhanced apoptosis was observed in SW872-S cells, which could be partially reversed by JNK or translation inhibitors.
  • Bortezomib more effectively inhibited MDR1 expression and function in SW872-S cells, correlating with increased proteasome inhibition.
  • Inhibition of SERCA2, highly expressed in SW872-S cells, partially reversed bortezomib-induced growth inhibition and increased MDR1 expression.

Conclusions:

  • Bortezomib exhibits preferential cytotoxicity towards highly malignant liposarcoma cells, potentially through SERCA2-associated MDR1 suppression.
  • The findings suggest bortezomib's potential as a therapeutic agent for advanced liposarcoma.
  • Further research into bortezomib's mechanisms and combination therapies is warranted.
Keywords:
ApoptosisBortezomibMDR1 proteinMalignant liposarcomaSERCA2SW872

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K